Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 25;11(11):1082.
doi: 10.3390/jpm11111082.

COVID-19 Advanced Care

Evangelia Fouka  1 , Ioannis Kalomenidis  2 , Niki Gianniou  2 , Sofia Gida  3 , Paschalis Steiropoulos  4
Affiliations
Review

COVID-19 Advanced Care

Evangelia Fouka et al. J Pers Med. .

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, related to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial burden in public health due to an enormous increase in hospitalizations for pneumonia with the multiorgan disease. Treatment for individuals with COVID-19 includes best practices for supportive management of acute hypoxic respiratory failure. Emerging data indicate that dexamethasone therapy reduces 28-day mortality in patients requiring supplemental oxygen compared with usual care, and ongoing trials are testing the efficacy of antiviral therapies, immune modulators and anticoagulants in the prevention of disease progression and complications, while monoclonal antibodies and hyperimmune globulin may provide additional preventive strategies. Consensus suggestions can standardize care, thereby improving outcomes and facilitating future research. This review discusses current evidence regarding the pharmacotherapy of COVID-19.

Keywords: SARS-CoV-2; antibiotics; anticoagulation; antiviral agents; monoclonal antibodies; passive immune therapies; severe acute respiratory syndrome; systemic corticosteroids.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest related to the above manuscript.

References

    1. Coronavirus Disease (COVID-19) Situation Reports. [(accessed on 23 August 2021)]. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio....
    1. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19—11 March 2020. [(accessed on 23 August 2021)]. Available online: https://www.who.int/director-general/speeches/detail/who-director-genera....
    1. The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. [(accessed on 23 August 2021)]; Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373339. - PMC - PubMed
    1. Leisman D.E., Ronner L., Pinotti R., Taylor M.D., Sinha P., Calfee C.S., Hirayama A.V., Mastroiani F., Turtle C.J., Harhay M.O., et al. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 2020;8:1233–1244. doi: 10.1016/S2213-2600(20)30404-5. - DOI - PMC - PubMed
    1. Shi Y., Wang Y., Shao C., Huang J., Gan J., Huang X., Bucci E., Piacentini M., Ippolito G., Melino G. COVID-19 infection: The perspectives on immune responses. Cell Death Differ. 2020;27:1451–1454. doi: 10.1038/s41418-020-0530-3. - DOI - PMC - PubMed

LinkOut - more resources